Yunnan Province Cancer Hospital ( Site 1643)

Kunming, Yunnan 650107

1 studies enrolling now · 1 studies all time

What they study most

Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

Studies at this site

• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) — Recruiting now